EMEA-001214-PIP01-11-M08
Key facts
| Invented name |
Fasenra
|
| Active substance |
benralizumab
|
| Therapeutic area |
Pneumology-allergology
|
| Decision number |
P/0244/2018
|
| PIP number |
EMEA-001214-PIP01-11-M08
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
Treatment of asthma
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
AstraZeneca AB (UK)
E-mail: paediatrics@medimmune.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|